Cargando…
Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
INTRODUCTION: Pre-existing conditions relevant for adverse events (AE) and the potential for drug–drug interactions (DDIs) may limit safe pharmacotherapeutic augmentation options for patients with major depressive disorder (MDD). This concern may be heightened among patients with treatment-resistant...
Autores principales: | Zhdanava, Maryia, Karkare, Swapna, Pilon, Dominic, Joshi, Kruti, Rossi, Carmine, Morrison, Laura, Sheehan, John, Lefebvre, Patrick, Lopena, Oliver, Citrome, Leslie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408057/ https://www.ncbi.nlm.nih.gov/pubmed/34368919 http://dx.doi.org/10.1007/s12325-021-01862-z |
Ejemplares similares
-
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
por: Zhdanava, Maryia, et al.
Publicado: (2020) -
Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021) -
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
por: Zhdanava, Maryia, et al.
Publicado: (2021) -
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022) -
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)